CD274 and non-small cell lung carcinoma: Hellmann et al. [7] reported that the combination of nivolumab plus ipilimumab yielded more favorable results than nivolumab monotherapy in patients with advanced NSCLC expressing programmed death-ligand 1 (PD-L1).